Of these patients, 233 were excluded from analysis because they were positive for hepatitis B surface antigen, hepatitis C antibody, or alcohol abuse or because they dropped out of our study in the subsequent 10 years. The remaining Bafilomycin A1 manufacturer 458 patients were allocated to two groups, a FL group (n =202; 109 males and 93 females, mean age was 64 years.) and a non-FL (NFL) group (n = 235; 155 males and 80 females,mean age was 62 years), based on US findings, and followed by a diabetologist and/or hepa-tologist for 10 years. The primary endpoint was occurrence of HCC and extrahepatic tumors. Cardiovascular events were a secondary endpoint. Results: During the observation

period, 24 patients were diagnosed with 24 gastrointestinal tumors, including 9 patients with gastric cancer (1.9%) and 4 patients with HCC (0.9%). Two HCC patients had past history of heavy drinking of alcohol. The etiology of HCC in the remaining two patients is unclear. No significant differences were observed between the FL group and NFL group in the occurrence rates of HCC, extrahepatic tumors, and cardiovascular events. However, in the FL group, the ALT serum level (>30 IU/L) was significantly associated with the incidence of macrovascular events in univariate (odds PKC412 datasheet ratio [OR], 5.296 (1.440-19.476) p=0.0084)

and multivariate (OR, 6.005 (1.555-23.182); p=0.0093) analyses.The γ-GTP serum level (>50IU/L) was a significant risk factor for extrahepatic tumors in all patients. Conclusion: A serum ALT level of 30 IU/L is an independent risk indicator of macrovascular disease in diabetic patients with FL, whereas the presence of FL itself in diabetes patients is not associated selleck inhibitor with an increased incidence of macrovas-cular events and malignancy. However, serum ALT level is a biomarker for cardiovascular events in patients with fatty liver. Disclosures: The following people have nothing to disclose: Masataka Seike, Koichi Honda, Junya Oribe, Mizuki Endo, Mie Yoshihara, Masanori Tokoro, Masao Iwao, Hiroki Syo, Kazunari Murakami [Background & aim] We recently reported that pre-menopausal women have

less severe fibrosis than men and post-meno-pausal women among patients with nonalcoholic steatohep-atitis (NASH), suggesting a protective effect of estrogens. We hypothesized that among postmenopausal women, those who had menopause at an earlier age are at an increased risk of hepatic fibrosis and that time after menopause positively correlates with fibrosis severity. In this analysis we aimed to investigate the associations of premature menopause (age at menopause of <40years) and the time from menopause with fibrosis severity among women with NAFLD. [Methods] We analyzed data from 491 post-menopausal women enrolled in the NASH CRN with 1) a histologic diagnosis of NAFLD and 2) self-reported information on age at menopause. Premature menopause was defined as age at menopause of <40 years (yrs).